Leucovorin prescriptions rise for autism amid ongoing research on symptom supports

Increased off-label use follows regulatory developments

Attention to leucovorin calcium's potential role in supporting some autistic individuals has grown following regulatory actions related to cerebral folate deficiency (CFD), a rare genetic condition diagnosed through specific blood tests and genetic screening. While the FDA updated labeling in 2025 for leucovorin's use in CFD, they clarified this approval was not for autism broadly. However, some clinicians have reported increased off-label prescribing, with one 2026 CNN report noting 'growing interest outpacing current evidence.'

Small studies have explored leucovorin's potential benefits for some autistic individuals, including research on Rett syndrome, though large controlled trials specifically examining autism remain limited. The Autism Research Institute emphasizes that current pharmacological approaches primarily focus on supporting co-occurring conditions rather than core autistic traits.

While the FDA updated labeling in 2025 for leucovorin's use in CFD, they clarified this approval was not for autism broadly.

Current support options

Only risperidone and aripiprazole have FDA approval for use with autistic individuals, specifically for supporting irritability. A 2026 Frontiers review examined how genetic differences (pharmacogenomics) might affect individual responses to risperidone, highlighting the importance of personalized approaches.

Emerging research directions

Scientists are investigating multiple approaches to support autistic individuals. Early-stage research includes examining vasopressin's potential role in social communication, though these studies remain preliminary. A comprehensive Nature review analyzed both pharmacological and microbiota-based approaches across animal and human studies, while other research explores compounds like levocarnitine in model systems.

Experts caution that while new developments bring hope, families and clinicians should consider the current evidence carefully. 'We need to balance scientific rigor with respect for neurodiversity,' one researcher told CNN. 'Promising early findings require thorough investigation before becoming standard supports.'